Clinical trial
Pemetrexed and Gemcitabine in Patients With Advanced Non-Small Cell Lung Cancer
NCT00193414 · SCRI Development Innovations, LLC, Other · Completed
Key facts
| NCT number | NCT00193414 |
|---|---|
| Title | Pemetrexed and Gemcitabine in Patients With Advanced Non-Small Cell Lung Cancer |
| Official title | Phase II Study of First-Line Therapy With Pemetrexed and Gemcitabine in Patients With Advanced Non-Small Cell Lung Cancer |
| Lead sponsor | SCRI Development Innovations, LLC, Other |
| Collaborators | Eli Lilly and Company Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Lung Cancer |
| Intervention type | Drug |
| Interventions | Pemetrexed, Gemcitabine |
| Enrollment | 72 |
| Start date | May 1, 2005 |
| Primary completion | Dec 1, 2008 |
| Completion | Aug 1, 2009 |
| First posted | Sep 19, 2005 |
| Last update posted | Mar 3, 2022 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: